CORRECTING and REPLACING PHOTO Zynga Celebrates Bugatti’s 110th Anniversary with Special CSR Racing 2 Event Series
4.12.2019 20:27:00 EET | Business Wire | Press release
Please replace the photo with the accompanying corrected photo.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191204005025/en/
Zynga Celebrates Bugatti’s 110th Anniversary with Special CSR Racing 2 Event Series (Photo: Business Wire)
The release reads:
ZYNGA CELEBRATES BUGATTI’S 110TH ANNIVERSARY WITH SPECIAL CSR RACING 2 EVENT SERIES
Players Can Race and Collect Exclusive Bugatti-Engineered Hyper Sports Cars in Game
Today, Zynga Inc. (Nasdaq: ZNGA), a global leader in interactive entertainment, is launching an event series in partnership with the hyper sports car manufacturer Bugatti in the hit mobile drag racing game, CSR Racing 2 (CSR2). The event series, which celebrates Bugatti’s 110th anniversary, will give players the opportunity to collect and compete with the world’s most powerful and exclusive hyper sports cars in CSR2.
“Bugatti is one of the most iconic and revered car manufacturers in the world, and we are truly honored to celebrate such an important milestone with them,” said Julian Widdows, Vice President of CSR2. “Our team worked tirelessly to make sure everything from the cars’ sleek forms to their powerful engines is authentically represented in the game. This is the closest an aficionado can come to owning a Bugatti without actually buying one.”
The series showcases 24 different Bugatti cars, three of which are available exclusively in CSR2. Players can view the cars in augmented reality, giving them the experience of sitting in the driver’s seats of the most desirable hyper sports cars ever designed. The integration has seven different events over an eight-week period, and will be highlighted in a continued beta version of CSR2’s new player-versus-player feature, Showdown.
CSR2 Bugatti Exclusives:
- Chiron Super Sport 300: the first series production car to break the magical 300 miles per hour barrier
- La Voiture Noire: a one-off one grand tourisme masterpiece
- Centodieci: the newly released homage to the original modern-day super sports car, EB110
“Interactive entertainment is a main driver for today’s young generation’s enthusiasm for cars and a great way to stay in touch with fans around the world,” said Bugatti President, Stephan Winkelmann. “We are very excited that through this partnership, our enthusiasts have the opportunity to experience all of our latest exclusive Bugatti hyper sports cars in CSR2.”
Every aspect of the 24 Bugatti cars, from the grills to the paint color, dashboard finish and stitching, has been meticulously recreated in CSR2 to mirror the real hyper sports cars. Players can explore the cars by tapping special points to trigger handcrafted, bespoke animations, allowing them to open doors, pop the hoods, inspect the engine bays, extend the spoilers and more.
CSR2 is available to download for free on the App Store as well as the Google Play Store. For more information about CSR2, visit the game’s community channels on Facebook, Twitter, Instagram, and YouTube.
Editor’s Note - To view the supporting assets for CSR Racing 2 (CSR2), please click here: https://app.box.com/s/56junq0iv8ibm2dx0mqfo8hpkd7qlk64
About Zynga Inc.
Zynga is a global leader in interactive entertainment with a mission to connect the world through games. To date, more than one billion people have played Zynga’s franchises including CSR Racing™, Empires & Puzzles™, Merge Dragons!™, Words With Friends™ and Zynga Poker™. Zynga’s games are available in more than 150 countries and are playable across social platforms and mobile devices worldwide. Founded in 2007, the company is headquartered in San Francisco with locations in the U.S., Canada, U.K., Ireland, India, Turkey and Finland. For more information, visit www.zynga.com or follow Zynga on Twitter and Facebook.
About Bugatti
Bugatti Automobiles S.A.S. manufactures the world's most powerful, fastest, most exclusive and luxurious production hyper sports car. Since its foundation in 1909, the French luxury brand has been based on and off in Molsheim, Alsace. The Veyron was made there between 2005 and 2015, the first modern-day hyper sports car, of which 450 vehicles were built by hand. Since autumn 2016, the staff in Molsheim have been producing the Chiron1 models.
With an output of 1,500 hp, which has never before been achieved by production vehicles, a torque of 1,600 newton metres at 2,000 to 6,000 rpm and numerous technical innovations, the Chiron1 has been setting new standards in automotive engineering ever since.
In 2017, Bugatti delivered 70 vehicles to customers, by 2018 this had increased to 76. More than 80 vehicles are set to be delivered to customers in 2019. Bugatti has announced the construction of 500 models – currently only 100 Chiron can be ordered. Production of the Divo2, a vehicle optimised for lateral acceleration, will follow soon.
Bugatti has been part of the Volkswagen Group since 1998 and employs more than 300 people. The majority of these work in Molsheim in Alsace. With 37 dealers and service partners in 18 countries in Europe, North America, the Middle East and Asia-Pacific, Bugatti is a global player.
1 Fuel consumption, l/100km: urban 35.2 / extra-urban 15.2 / combined 22.5; combined CO2 emissions, g/km: 516; efficiency class: G
2 Fuel consumption, l/100km: not subject to Directive 1999/94/EC as overall type approval is currently not yet available
Forward Looking Statement
This press release contains forward-looking statements, relating to, among other things, the release of future CSR Racing 2 game features and events. Forward-looking statements often include words such as "outlook," "projected," “planned,” "intends," "will," "anticipate," "believe," "target," "expect," and statements in the future tense are generally forward-looking. The achievement or success of the matters covered by such forward-looking statements involves significant risks, uncertainties, and assumptions. Undue reliance should not be placed on such forward-looking statements, which are based on information available to us on the date hereof. We assume no obligation to update such statements. More information about these risks, uncertainties, and assumptions are or will be described in greater detail in our public filings with the Securities and Exchange Commission (the "SEC"), copies of which may be obtained by visiting our Investor Relations web site at http://investor.zynga.com or the SEC's web site at www.sec.gov
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191204005025/en/
Contact information
Zynga Media Contact:
Kenny Johnston
kjohnston@zynga.com | (602) 999-1890
Or
Bugatti Automobiles S.A.S. Contact:
Tim Bravo
Head of Communications
Mobile: +33 640 151969
Email: tim.bravo@bugatti.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
